Paradigm Biopharma Advances Clinical Trials with Fiscal Prudence

Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.

Paradigm Biopharmaceuticals Ltd. has actively engaged with the US FDA for the advancement of its Phase 3 osteoarthritis clinical program and attended the influential Bio International Conference to foster industry connections. The company reported lower-than-expected quarterly cash outflows, maintaining a strong cash balance by implementing cost containment measures, with a focus on directing funds towards high-value clinical programs. Paradigm also awaits a response from the US FDA on their submission and has applied for TGA provisional approval in Australia.

For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.